Citi maintains a sell rating on Persistent (TP: Rs 3,080). Q1 shows strong growth but expects sequential margin decline, with Q2 at risk due to wage hikes. Market worries over FY25 margins and stable TCV. Despite a 24% rise, stock beats IT index by 17%. UBS reiterates buy on Dr. Lal Path Labs (TP: Rs 3,500). Potential growth reinvestment not priced in, Tier-3 markets perform well.
